Anthony Rosenberg

Global Head of Business Development and Licensing, Novartis Pharma AG

« Back to Board of Directors

RosenbergAnthony Rosenberg has served as a director since June 2009. Mr. Rosenberg is Head of Business Development and Licensing of Novartis Pharma AG and a member of the Pharma Executive Committee. He joined Sandoz in 1980 in the UK where he held various leadership positions in sales and marketing, business development and strategic planning. In 1994 he moved to Basel, initially as international product manager (Clozaril), and undertook roles of increasing responsibility in Global Marketing, ultimately as Head Global Marketing Primary Care. In 2000 he became Global Head of the Transplant and Immunology Business Unit and began his current role in 2005. He has overseen several major in-licensing transactions in the respiratory, infectious disease, CNS areas. Tony Rosenberg has a BSc (Biological Sciences) University of Leicester, and an M.Sc (Physiology) University of London.

 

 

 

Idenix has focused its efforts towards HCV due to the global unmet medical need for this viral disease. It is estimated that more than 170 million people worldwide are chronically infected with HCV.